📋 Tender Overview
Grant agreement ID: 101309891
DOI
10.3030/101309891
EC signature date
11 June 2026
Start date
1 October 2026
End date
30 September 2030
Objective
In the era of precision medicine, we face a startling paradox: while sequencing entire genomes is routine, we remain blind to thousands of small open reading frames (smORFs) encoding microproteins that constitute a vast dark proteome. Recent breakthroughs have revealed their critical roles in diverse biological processes. This previously overlooked layer represents a fundamental gap in our understanding of cellular function and a major untapped source of therapeutic opportunities. Despite growing recognition by initiatives like Cancer Research UK Grand Challenges, the field remains critically immature with fragmented research, non-standardized methodologies, and most critically, an acute shortage of scientists with multidisciplinary expertise. This human capital bottleneck prevents Europe from establishing leadership.
ORFeus addresses this by training 15 interdisciplinary scientists bridging computational biology, proteogenomics, and therapeutic development. Our consortium unites 15 leading European academics with 14 strategic industry partners spanning technology pioneers, AI innovators, and pharmaceutical developers. Through mandatory integrated training, industry secondments, and cutting-edge technologies, every researcher becomes both computationally and experimentally proficient, a crucial 'bilingual' skillset currently unavailable through traditional programs.
The program delivers groundbreaking innovations: AI-powered prediction tools, standardized workflows through the open-access ORFeome platform, and novel cancer immunotherapy targets. By creating Europe's first comprehensive dark proteome training program, ORFeus transforms this fragmented field into a mature research domain. Our graduates will drive innovation across academia and biotechnology, translate discoveries into clinical applications, and secure Europe's leadership in illuminating this vast unexplored dimension of human biology with profound implications for precision medicine.
